Patents Assigned to Georgetown University
-
Patent number: 11357742Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.Type: GrantFiled: December 14, 2016Date of Patent: June 14, 2022Assignees: X4 Pharmaceuticals, Inc., Georgetown University, Beth Israel Deaconess Medical Center, Inc.Inventors: Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
-
Publication number: 20220168277Abstract: A method for treating against, or at least inhibiting or suppressing, the proliferation of a cancer involves administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting metastasis of cancer cells, wherein the compound is represented by the formula (1): wherein each R1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo.Type: ApplicationFiled: March 25, 2020Publication date: June 2, 2022Applicants: HOWARD UNIVERSITY, GEORGETOWN UNIVERSITYInventors: Hemayet ULLAH, Sivanesan DAKSHANAMURTHY
-
Patent number: 11311526Abstract: Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.Type: GrantFiled: March 31, 2017Date of Patent: April 26, 2022Assignees: Georgetown University, The Board of Regents of the University of OklahomaInventors: Milton L. Brown, Yali Kong, Courtney Houchen, Sripathi M. Sureban, Parthasarathy Chandrakesan
-
Patent number: 11311606Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.Type: GrantFiled: March 12, 2019Date of Patent: April 26, 2022Assignee: GEORGETOWN UNIVERSITYInventors: Christopher Albanese, Aisha Naeem
-
Publication number: 20220104732Abstract: A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the user's skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.Type: ApplicationFiled: December 16, 2021Publication date: April 7, 2022Applicant: Georgetown UniversityInventors: Makarand Paranjape, Shruti M. Paranjape
-
Patent number: 11295417Abstract: A system and method are described for enhancing readability of document images by operating on each document individually. Monochromatic light sources operating at different wavelengths of light can be used to obtain greyscale images. The greyscale images can then be used in any desired image enhancement algorithm. In one example algorithm, an automated method removes image background noise and improves sharpness of the scripts and characters using edge detection and local color contrast computation.Type: GrantFiled: May 26, 2020Date of Patent: April 5, 2022Assignee: Georgetown UniversityInventors: Ophir Frieder, Gideon Frieder, Jon Parker
-
Publication number: 20220096442Abstract: A method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site-utilizing virus (IRES-utilizing virus) involves administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: wherein each R1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo.Type: ApplicationFiled: October 29, 2019Publication date: March 31, 2022Applicants: HOWARD UNIVERSITY, GEORGETOWN UNIVERSITYInventors: Hemayet ULLAH, Sivanesan DAKSHANAMURTHY
-
Patent number: 11280797Abstract: The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.Type: GrantFiled: February 2, 2018Date of Patent: March 22, 2022Assignees: Georgetown University, University of RochesterInventors: Mark E. Mapstone, Howard J. Federoff, Massimo S. Fiandaca, Amrita K. Cheema
-
Patent number: 11278551Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.Type: GrantFiled: March 15, 2018Date of Patent: March 22, 2022Assignee: GEORGETOWN UNIVERSITYInventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
-
Patent number: 11278522Abstract: Previous studies (Xiao et al., 2001) have identified two metabolites of methadone, EMDP (2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline) and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), which are considered to be inactive at opiate receptors, as relatively potent noncompetitive channel blockers of ?3?4 nAChRs. We have now evaluated these compounds in rats and mice in preclinical behavioral models predictive of potential anxiolytic and antidepressant efficacy. We found that EMDP, but not EDDP, displayed robust effects predictive of anxiolytic and antidepressant efficacy without significant effects on locomotor activity. Moreover, EMDP at behaviorally active doses, unlike mecamylamine, did not produce eyelid ptosis, suggesting it may produce fewer autonomic side effects than mecamylamine. Thus, the methadone metabolite EMDP may represent a novel therapeutic avenue for the treatment of some affective disorders.Type: GrantFiled: July 13, 2020Date of Patent: March 22, 2022Assignee: Georgetown UniversityInventors: Kenneth J. Kellar, Yingxian Xiao, Patrick A. Forcelli
-
Publication number: 20220065863Abstract: Methods of treating with radiation therapy a subject having cancer, in which the method comprises administering radiation therapy to the subject. The subject does not have an increased risk of having an adverse reaction to radiation therapy. The subject has an increased risk of an adverse reaction to radiation therapy when the subject's level of each component in a component profile from a sample of the subject is altered as compared to the normal level of each component. The component profile may comprise a metabolite panel of geranyl pyrophosphate, glucose-1-phosphate, and 3-hydroxy-3-methylglutaryl-CoA; a lipid panel of LPA 18:0, LPA 16:0, LPC 20:2, CER 24:0, and LPI 16:1; or a combination of these panels. The component profile may also comprise a metabolite panel of metanephrine, tryptophan, xanthurenic acid, and pantothenate; a lipid panel of LPA 18:0, DAG 16:0/18:0, LPA 16:0, and DAG 18:1/18:1; or a combination of these panels.Type: ApplicationFiled: September 15, 2021Publication date: March 3, 2022Applicant: Georgetown UniversityInventors: Anatoly Dritschilo, Amrita K. Cheema, Scott Grindrod, Xiaogang Zhong
-
Patent number: 11246881Abstract: A construct, or a pharmaceutically acceptable salt thereof, comprising: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a siRNA complexed with the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.Type: GrantFiled: March 15, 2017Date of Patent: February 15, 2022Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Georgetown UniversityInventors: Jill P. Smith, Stephan Stern, Abdullah Mahmud
-
Patent number: 11247206Abstract: A system for determining the presence of cell-free non-coding RNA (cfNCR) biomarkers in interstitial fluid includes a microfluidic device for non-invasively and passively accessing interstitial fluid from a patient. The microfluidic device is formed of a substrate containing multiple vertical micro channels therethrough, wherein at a first end of each of the multiple vertical micro channels a microheater is formed for controllably ablating a portion of dry dead skin cells to access the interstitial fluid; and wherein at a second end of each of the multiple vertical micro channels is a horizontal micro channel for receiving accessed interstitial fluid from a vertical micro channel and guiding the accessed interstitial fluid to a common collection port.Type: GrantFiled: January 31, 2018Date of Patent: February 15, 2022Assignee: Georgetown UniversityInventor: Makarand Paranjape
-
Patent number: 11238966Abstract: Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.Type: GrantFiled: November 3, 2020Date of Patent: February 1, 2022Assignee: Georgetown UniversityInventors: Ophir Frieder, Hao-Ren Yao, Der-Chen Chang
-
Patent number: 11232869Abstract: A triage system that determines whether a user is likely to have contracted a disease based on sensor data received from a user device (e.g., a smartphone or activity tracker). Some symptoms are identified by comparing sensor data to a predetermined baseline and comparing the difference to a predetermined symptom threshold. Those comparisons are weighted to form a composite metric, which is compared to a composite threshold to determine if the user is likely to have contracted the disease. Because different individuals are at higher risk of contracting certain diseases, the determined based on specific characteristics of the user (e.g., potential comorbidities, age, gender, ethnic, racial, cultural, or economic status, geographic location, level of interaction with other individuals, etc.) that that have been identified in medical literature as increasing the individual's risk.Type: GrantFiled: August 18, 2020Date of Patent: January 25, 2022Assignee: Georgetown UniversityInventors: Howard Federoff, Ophir Frieder
-
Patent number: 11226945Abstract: A knowledge model “overlay” for organizing and analyzing large, dynamic data volumes is implemented as a hypergraph that manifests as a result of a distributed theory-driven data source transformation process. This process maps exponentially growing data into an asymptotically limited information space. Within this space, real-world entities (e.g. people, computers, cities, Earth) and their complex interdependencies (e.g. social networks, connectivity, causal relationships) are represented as attributed hypergraph elements (i.e. both hypervertices and hyperedges). Attributes are represented as state vectors affixed to any hypergraph element. Transformation of source system data into this overlay structure is accomplished with minimal data movement and replication using a universal “pointer” like mechanism that is managed in a decentralized fashion by the respective transformation components.Type: GrantFiled: May 24, 2019Date of Patent: January 18, 2022Assignee: Georgetown UniversityInventor: J. Cory Smart
-
Patent number: 11219390Abstract: A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the user's skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.Type: GrantFiled: August 2, 2016Date of Patent: January 11, 2022Assignee: Georgetown UniversityInventors: Makarand Paranjape, Shruti M. Paranjape
-
Publication number: 20220000819Abstract: Provided herein are methods for treating nonalcoholic steatohepatitis (NASH) in a subject, comprising administering to a subject having NASH an effective amount of a CCK receptor inhibitor.Type: ApplicationFiled: November 5, 2019Publication date: January 6, 2022Applicant: GEORGETOWN UNIVERSITYInventor: Jill P. SMITH
-
Publication number: 20220000842Abstract: The present application is directed to methods and compositions for treating a condition marked by enhanced inflammation in the central nervous system (CNS). The methods comprise administering to a subject in need of treatment of enhanced inflammation in the CNS an inhibitor of an amino acid transporter in inflammatory cells present in the CNS. The compositions of the present invention relate to compositions comprising an inhibitor of an amino acid transporter in inflammatory cells, or a pharmaceutically acceptable salt thereof, wherein the composition is formulated for direct administration into the CNS of a mammal.Type: ApplicationFiled: October 2, 2019Publication date: January 6, 2022Applicant: Georgetown UniversityInventors: Jeffrey Huang, Maryna Baydyuk
-
Patent number: 11202792Abstract: Provided herein are methods of treating a bone or connective tissue cancer in a subject. The methods comprise administering to the subject an effective amount of a CD99 inhibitor, wherein the CD99 inhibitor is a compound having the formula wherein R, each of which may be the same or different, is hydrogen, or a protecting group; wherein Z is selected from the group consisting of F, Cl and Br; wherein X is H or F; and pharmaceutically acceptable salts thereof.Type: GrantFiled: October 12, 2017Date of Patent: December 21, 2021Assignee: GEORGETOWN UNIVERSITYInventors: Aykut Üren, Haydar Celik, Jeffrey A. Toretsky